Prothena Reports First Quarter 2017 Financial Results and Provides R&D Update

DUBLIN, Ireland, May 09, 2017 (GLOBE NEWSWIRE) — Prothena Corporation plc (PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today reported financial results for the first quarter of 2017. In addition, the Company provided an update on its R&D programs.